Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 13, 2018. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports specific share acquisition transactions.
| Transaction Date | Instrument | Transaction Price | Total Volume | Exchange |
|---|---|---|---|---|
| July 12, 2018 | Ordinary Shares (25p each) | £15.7040 | 320 shares | London Stock Exchange (XLON) |
Note: The total volume of 320 shares is the aggregate of individual transactions by nine executives.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of ordinary shares by executives following the re-investment of dividends paid on July 12, 2018, under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Executives Involved: Transactions were executed by nine senior leaders, including CEO Emma Walmsley, CFO Simon Dingemans, and President of Global Pharmaceuticals Luc Miels.
- Share Price: The execution price for all transactions was £15.7040 per share.
- Volume: The total number of shares acquired by these executives in this specific batch was 320.
- Limitation: This filing does not provide data on GSK's overall financial performance for the period.